新诺威：控股子公司SYS6023抗体偶联药物获临床试验批准

Core Viewpoint - XinNuoWei (300765) announced that its subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SYS6023, an antibody-drug conjugate targeting HER3, aimed at treating unresectable locally advanced or metastatic breast cancer [1] Group 1 - The SYS6023 drug is designed to utilize a self-developed topoisomerase I inhibitor payload, which is expected to avoid drug resistance through efflux mechanisms [1]